home / stock / aimd / aimd news

AIMD News and Press, Ainos Inc From 11/28/23

Stock Information
Company Name: Ainos Inc
Stock Symbol: AIMD
Market: OTC
Website: ainos.com
Menu
AIMD AIMD Quote AIMD Short AIMD News AIMD Articles AIMD Message Board
Get AIMD Alerts

News, Short Squeeze, Breakout and More Instantly...
AIMD - Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Subsequent Phase Involves Completion of Chemistry, Manufacturing, and Controls (CMC) Information Ainos Intends to Submit Investigational New Drug Applications to the U.S. FDA for Multiple Candidates During the First Half of 2024 Candidates include HIV Oral Warts Orphan Drug, Sjogren's S...
AIMD - Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Data partially fulfills the safety and efficacy hypotheses of one pilot and two Phase II clinical studies Ainos aims to pursue a pre-IND meeting with the U.S. FDA ahead of a planned Phase III study SAN DIEGO, CA / ACCESSWIRE / November 21, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos...

AIMD - Ainos GAAP EPS of -$0.15

2023-11-10 09:07:15 ET More on Ainos Ainos to issue initial $3M tranche of $10M private placement of notes Financial information for Ainos For further details see: Ainos GAAP EPS of -$0.15

AIMD - Ainos Reports Third Quarter 2023 Financial Results

Product Cycle Transition Approaches its Final Stages New Product Line Expected to Gain Momentum in the Fourth Quarter SAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development...
AIMD - Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA

Ainos and SIDSCO will cooperate to accelerate the development of new animal drugs based on Ainos' VELDONA® low-dose oral interferon Upcoming clinical study will investigate VELDONA®'s safe use and efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosa...

AIMD - Expected US Company Earnings on Monday, November 6th, 2023

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

AIMD - Ainos to issue initial $3M tranche of $10M private placement of notes

2023-09-25 08:56:23 ET More on Ainos Financial information for Ainos For further details see: Ainos to issue initial $3M tranche of $10M private placement of notes
AIMD - Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement

Proceeds to fund company's clinical trials, commercial product launch, and working capital Initial conversion price set at $1.50 per share SAN DIEGO, CA / ACCESSWIRE / September 25, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company fo...

AIMD - With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients

Boston, Massachusetts--(Newsfile Corp. - September 19, 2023) - The U.S. Food and Drug Administration (FDA) has granted Ainos' (NASDAQ: AIMD) VELDONA Orphan Drug Designation (ODD) for the treatment of oral warts in HIV-seropositive patients. VELDONA is Very Low-Dose Oral Interferon Alpha, Ainos' p...

AIMD - Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients

VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive Americans SAN DIEGO, CA / ACCESSWIRE / September 18, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of AI-powered point...
Previous 10 Next 10